The disease relevance of human hepatocellular xenograft models: molecular characterization and review of the literature.

In recent years a number of new therapeutics has been developed that were not general toxins and inhibitors of cell division like classical chemotherapeutics, but were designed to target a specific pathway. A prerequisite for this development was the comprehensive characterization of molecular alterations occurring in human hepatocellular carcinoma (HCC). However, while much knowledge of the molecular pathogenesis of human HCC has been gained, the model systems used to test the functional relevance of these alterations and applied for preclinical evaluation of drug candidates are still poorly characterized. In this paper, we reviewed the literature about several commonly used HCC cell lines and xenotransplantation models and present our own data on the molecular characterization of these. Results obtained demonstrate that it is important to have a sound knowledge of the specific molecular constitution of the experimental model and to carefully evaluate the functional status of the pathway of interest. For this reason, we make the gene expression profiles publicly available to help researchers making an informed decision about which model to use.

[1]  David S. Taylor,et al.  Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  N. Tamaoki,et al.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. , 1981, Journal of immunology.

[3]  Alona Muzikansky,et al.  Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Giovanella,et al.  Development of invasive tumors in the "nude" mouse after injection of cultured human melanoma cells. , 1972, Journal of the National Cancer Institute.

[5]  Ivan Damjanov,et al.  Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line , 1979, Nature.

[6]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[7]  P. Schein,et al.  Barriers to Efficient Development of Cancer Therapeutics , 2006, Clinical Cancer Research.

[8]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[9]  H. Wortis,et al.  ABNORMAL DEVELOPMENT OF THE THYMUS IN "NUDE" MICE , 1971, The Journal of experimental medicine.

[10]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.

[11]  D. Greiner,et al.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.

[12]  Jeffrey W. Clark,et al.  Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.

[13]  F. Alt,et al.  Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation , 1995, Cell.

[14]  R. Custer,et al.  A severe combined immunodeficiency mutation in the mouse , 1983, Nature.

[15]  D. Schmähl,et al.  Zur Morphologie der durch Diäthylnitrosamin erzeugten Lebertumoren bei der Maus und dem Meerschweinchen , 1963, Zeitschrift für Krebsforschung.

[16]  Yoshihiro Yamanishi,et al.  KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..

[17]  Guan-Tarn Huang,et al.  Hepatocyte Growth Factor Stimulates the Growth and Activates Mitogen-Activated Protein Kinase in Human Hepatoma Cells , 1998, Journal of Biomedical Sciences.

[18]  Derek Y. Chiang,et al.  Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.

[19]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[20]  M R Grever,et al.  In vivo cultivation of tumor cells in hollow fibers. , 1995, Life sciences.

[21]  K. Kaestner,et al.  Unified nomenclature for the winged helix/forkhead transcription factors. , 2000, Genes & development.

[22]  B. Carr,et al.  Concomitant and isolated expression of TGF‐alpha and EGF‐R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma , 1995, Journal of surgical oncology.

[23]  I. Fidler,et al.  Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental metastasis , 1982, International journal of cancer.

[24]  K. Chai,et al.  In vitro anti-proliferative effect of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose on human hepatocellular carcinoma cell line, SK-HEP-1 cells. , 2001, Cancer letters.

[25]  S. Kuo,et al.  CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression. , 2007, Cancer letters.

[26]  S. Heffelfinger,et al.  SK HEP-1: A human cell line of endothelial origin , 1992, In Vitro Cellular & Developmental Biology - Animal.

[27]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Cristel G. Thomas,et al.  Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry , 2007, Hepatology.

[29]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[30]  T. Orfeo,et al.  One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. , 1977, Journal of the National Cancer Institute.

[31]  Li Zhao,et al.  Expression of cancer-testis antigens in hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[32]  J. Rygaard,et al.  Heterotransplantation of a human malignant tumour to "Nude" mice. , 2009, Acta pathologica et microbiologica Scandinavica.

[33]  H. Hirte,et al.  BAY 43-9006: early clinical data in patients with advanced solid malignancies. , 2002, Current pharmaceutical design.

[34]  J. Venditti,et al.  Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. , 1984, Advances in pharmacology and chemotherapy.

[35]  M. Kojiro,et al.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma , 1998, Hepatology.

[36]  Y. Watanabe,et al.  Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. , 2008, Liver.

[37]  Thomas Boehm,et al.  New member of the winged-helix protein family disrupted in mouse and rat nude mutations , 1994, Nature.

[38]  S. Flanagan,et al.  'Nude', a new hairless gene with pleiotropic effects in the mouse. , 1966, Genetical research.

[39]  S. Thorgeirsson,et al.  Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.

[40]  Jeffrey S. Morris,et al.  Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma , 2007, Cancer.

[41]  J. Sheu Molecular mechanism of hepatocarcinogenesis , 1997, Journal of gastroenterology and hepatology.

[42]  A. Groen,et al.  Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. , 1994, The American journal of pathology.

[43]  M. Bibby,et al.  50 years of preclinical anticancer drug screening: empirical to target-driven approaches. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  Rolf Gebhardt,et al.  Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma , 2008, Molecular Cancer.

[45]  H. Kawasaki,et al.  Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. , 1999, Liver.

[46]  G. Giannelli,et al.  Novel Concepts in Hepatocellular Carcinoma: From Molecular Research to Clinical Practice , 2006, Journal of clinical gastroenterology.